The proposed Met-CVRD nomenclature places metabolic dysfunction as the primary driver of the cardiovascular-renal disease syndrome, not just a comorbidity.
Met-CVRDProposed nomenclature placing metabolic dysfunction as the primary driver of cardiovascular-renal disease
What the researchers found
Metabolic dysfunction drives cardiovascular-renal disease and deserves primary positioning in the syndrome nomenclature as Met-CVRD.
Why it matters
Naming matters — putting "metabolic" first prioritizes upstream treatment of the root cause rather than downstream management of heart and kidney symptoms.
The numbers in context
No specific trial data; conceptual paper with terminology proposal.
How the study worked
Expert commentary/nomenclature proposal with pathophysiological rationale.
Who was studied
Patients with type 2 diabetes and cardiovascular-renal comorbidities
What this study cannot tell us
Expert opinion/nomenclature proposal — no new clinical data. Name adoption requires consensus across multiple specialties.
How to read the evidence
Expert commentary — provides conceptual framework supported by existing evidence but no new data.
When this study was published
Published in 2025, reflecting the evolving understanding of metabolic disease as a systemic driver.
The bigger picture
This nomenclature shift could influence clinical guidelines, research priorities, and drug development toward metabolic-first treatment strategies.
Questions still open
- Will the Met-CVRD terminology be adopted by major guideline committees?
- Does metabolic-first treatment actually improve long-term outcomes more than organ-specific approaches?
Common questions
What is Met-CVRD?
Why does the name of a disease matter?
Read the original research
Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nomenclature.
Diabetes/metabolism research and reviews, 41(6), e70083
Citation
Pozzilli, Paolo; Messina, Maria Vittoria; Roden, Michael. (2025). Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nomenclature.. Diabetes/metabolism research and reviews, 41(6), e70083. https://doi.org/10.1002/dmrr.70083